Business · 18/10/2026

AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio

AbbVie is set to present new and updated data on its expanding portfolio of treatments for various types of cancer, including lung, colorectal, ovarian, prostate, and gastric cancers, at the 2026 ESMO Congress, showcasing the potential of its next-generation antibody-drug conjugates (ADCs) to address diverse patient needs.